Duvelisib has been shown to inhibit CAR-T induced interleukin-6 (IL-6) production from immature dendritic cells while demonstrating no inhibitory effect on CAR-T, thus minimizing cytokine release syndrome (CRS) related to CAR-T cell therapy in vitro and in vivo, which warrant further evaluation of its utilization in the treatment of CAR-T-associated CRS [263]. Here, IL6 is linked to congenital rubella syndrome.